CN102628082B - 基于高通量测序技术进行核酸定性定量检测的方法 - Google Patents
基于高通量测序技术进行核酸定性定量检测的方法 Download PDFInfo
- Publication number
- CN102628082B CN102628082B CN201210103138.5A CN201210103138A CN102628082B CN 102628082 B CN102628082 B CN 102628082B CN 201210103138 A CN201210103138 A CN 201210103138A CN 102628082 B CN102628082 B CN 102628082B
- Authority
- CN
- China
- Prior art keywords
- primer
- sequence
- nucleic acid
- goal gene
- pcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 79
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 34
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 34
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 34
- 238000005516 engineering process Methods 0.000 title claims abstract description 31
- 238000012163 sequencing technique Methods 0.000 title claims abstract description 22
- 108020004414 DNA Proteins 0.000 claims abstract description 80
- 230000003321 amplification Effects 0.000 claims abstract description 15
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 15
- 238000001514 detection method Methods 0.000 claims abstract description 14
- 102000053602 DNA Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 61
- 239000012634 fragment Substances 0.000 claims description 32
- 238000012408 PCR amplification Methods 0.000 claims description 29
- 108090001008 Avidin Proteins 0.000 claims description 23
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 108091036060 Linker DNA Proteins 0.000 claims description 17
- 229930003756 Vitamin B7 Natural products 0.000 claims description 14
- 238000004445 quantitative analysis Methods 0.000 claims description 14
- 239000011735 vitamin B7 Substances 0.000 claims description 14
- 235000011912 vitamin B7 Nutrition 0.000 claims description 14
- 238000012165 high-throughput sequencing Methods 0.000 claims description 13
- 230000000813 microbial effect Effects 0.000 claims description 13
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 9
- 108010090804 Streptavidin Proteins 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- 238000005259 measurement Methods 0.000 claims description 9
- 238000004451 qualitative analysis Methods 0.000 claims description 9
- 238000013016 damping Methods 0.000 claims description 8
- 239000007790 solid phase Substances 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 210000002969 egg yolk Anatomy 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000012353 t test Methods 0.000 claims description 3
- 239000004005 microsphere Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000004907 flux Effects 0.000 abstract description 2
- 238000003753 real-time PCR Methods 0.000 abstract 2
- 244000005700 microbiome Species 0.000 description 24
- 239000000523 sample Substances 0.000 description 23
- 239000000203 mixture Substances 0.000 description 20
- 238000000746 purification Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 238000001190 Q-PCR Methods 0.000 description 9
- 210000003754 fetus Anatomy 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 238000013467 fragmentation Methods 0.000 description 8
- 238000006062 fragmentation reaction Methods 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 239000002689 soil Substances 0.000 description 6
- 239000011534 wash buffer Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000011324 bead Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 201000002313 intestinal cancer Diseases 0.000 description 5
- 206010025482 malaise Diseases 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000012148 binding buffer Substances 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000004252 chorionic villi Anatomy 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000001921 nucleic acid quantification Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical group O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010056254 Intrauterine infection Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 208000036830 Normal foetus Diseases 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000011000 absolute method Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000001754 blood buffy coat Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000013368 commensalism Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- BGOFCVIGEYGEOF-UJPOAAIJSA-N helicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1C=O BGOFCVIGEYGEOF-UJPOAAIJSA-N 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical group C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 238000009609 prenatal screening Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 235000019587 texture Nutrition 0.000 description 1
- WHLUQAYNVOGZST-UHFFFAOYSA-N tifenamil Chemical group C=1C=CC=CC=1C(C(=O)SCCN(CC)CC)C1=CC=CC=C1 WHLUQAYNVOGZST-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210103138.5A CN102628082B (zh) | 2012-04-10 | 2012-04-10 | 基于高通量测序技术进行核酸定性定量检测的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210103138.5A CN102628082B (zh) | 2012-04-10 | 2012-04-10 | 基于高通量测序技术进行核酸定性定量检测的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102628082A CN102628082A (zh) | 2012-08-08 |
CN102628082B true CN102628082B (zh) | 2014-09-17 |
Family
ID=46586473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210103138.5A Expired - Fee Related CN102628082B (zh) | 2012-04-10 | 2012-04-10 | 基于高通量测序技术进行核酸定性定量检测的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102628082B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103602726B (zh) * | 2013-10-21 | 2015-06-03 | 田埂 | 同时对多种核酸样本进行测序的方法 |
CN104963000B (zh) * | 2014-12-15 | 2021-04-06 | 杭州贝瑞和康基因诊断技术有限公司 | 一种快速构建单细胞dna测序文库的方法和试剂盒 |
CN107002080B (zh) * | 2014-12-18 | 2020-11-06 | 深圳华大智造科技股份有限公司 | 一种基于多重pcr的目标区域富集方法和试剂 |
CN105200154B (zh) * | 2015-11-02 | 2016-11-09 | 艾吉泰康生物科技(北京)有限公司 | Brca1和brca2基因突变的多重pcr检测方法和试剂盒 |
CN106834107A (zh) * | 2017-03-10 | 2017-06-13 | 首度生物科技(苏州)有限公司 | 一种基于二代测序的预测肿瘤系统 |
CN107699957B (zh) * | 2017-05-27 | 2021-07-23 | 领星生物科技(上海)有限公司 | 基于dna的融合基因定量测序建库、检测方法及其应用 |
CN110875082B (zh) * | 2018-09-04 | 2022-05-31 | 深圳华大因源医药科技有限公司 | 一种基于靶向扩增测序的微生物检测方法和装置 |
CN111690724B (zh) * | 2019-03-15 | 2022-04-26 | 北京大学 | 一种检测双链断裂产生试剂活性的方法 |
CN110438199A (zh) * | 2019-08-15 | 2019-11-12 | 深圳谱元科技有限公司 | 一种新型病原微生物检测的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100028873A1 (en) * | 2006-03-14 | 2010-02-04 | Abdelmajid Belouchi | Methods and means for nucleic acid sequencing |
CN102344961B (zh) * | 2011-09-30 | 2015-12-09 | 北京康旭医学检验所有限公司 | 一种经济的应用大规模平行测序技术检验多目标多基因的方法 |
-
2012
- 2012-04-10 CN CN201210103138.5A patent/CN102628082B/zh not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
刘博等.应用于染色体步移的PCR 扩增技术的研究进展.《遗传》.2006,第28卷(第5期), |
应用于染色体步移的PCR 扩增技术的研究进展;刘博等;《遗传》;20061231;第28卷(第5期);第588-589页 * |
Also Published As
Publication number | Publication date |
---|---|
CN102628082A (zh) | 2012-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102628082B (zh) | 基于高通量测序技术进行核酸定性定量检测的方法 | |
JP6106636B2 (ja) | 2型腫瘍症(neoplasms−ii)の診断法 | |
AU774214B2 (en) | Methods for stool sample preparation | |
JP2010279394A (ja) | 疾患検出のための方法 | |
CN109112216B (zh) | 三重qPCR检测DNA甲基化的试剂盒和方法 | |
WO2021180106A1 (zh) | 一种检测消化道5种肿瘤的探针组合物 | |
CN113999901B (zh) | 心肌特异性甲基化标记物 | |
TWI815043B (zh) | 腫瘤檢測試劑及試劑盒 | |
CN112210601A (zh) | 基于粪便样本的结直肠癌筛查试剂盒 | |
CN115572765A (zh) | 一组肿瘤检测标志物及其用途 | |
JP5258760B2 (ja) | メチル化核酸又は非メチル化核酸を増幅する方法 | |
US20040259101A1 (en) | Methods for disease screening | |
CN116970705B (zh) | 用于尿路上皮癌基因甲基化检测的核酸产品、试剂盒及应用 | |
CN114107498B (zh) | 结直肠癌血液检测标记物及其应用 | |
CN112210602B (zh) | 基于粪便样本的结直肠癌筛查方法 | |
WO2024001668A1 (zh) | 用于检测肺结节良恶性的甲基化分子标记物及其应用 | |
CN118147311B (zh) | 尿路上皮癌甲基化标志物试剂盒 | |
CN115851959B (zh) | 一种用于食管鳞状细胞癌及癌前病变的诊断或辅助诊断的试剂及检测试剂盒 | |
CN114941028B (zh) | 结直肠癌的检测和诊断的试剂及试剂盒 | |
CN113817818B (zh) | 用于诊断过敏性气道炎症的工具 | |
CN118957075A (zh) | 用于肺癌甲基化检测的探针组、试剂盒及检测系统和应用 | |
CN118064590A (zh) | 检测膀胱癌的核酸组合产品及其应用 | |
CN117248021A (zh) | 一种用于尿路上皮癌或癌前病变检测的核酸组合、试剂盒及应用 | |
CN115044671A (zh) | 可用于胃癌her2伴随诊断的基因甲基化标记物或其组合和应用 | |
CN117887897A (zh) | 一种鹅腺病毒4型的pcr检测引物及其试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: CHEMOGENE BIOTECHNOLOGIES SUZHOU Ltd. Document name: Notification that Application Deemed not to be Proposed |
|
ASS | Succession or assignment of patent right |
Owner name: ZHANG YINGPIN Free format text: FORMER OWNER: KAIJING BIOLOGICAL TECHNOLOGY (SUZHOU) CO., LTD. Effective date: 20131223 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 215123 SUZHOU, JIANGSU PROVINCE TO: 650200 KUNMING, YUNNAN PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20131223 Address after: 650200, No. 2, unit 5, 31 Tung Wan, Guandu District, Yunnan, Kunming Applicant after: Zhang Yingpin Address before: Linquan Street Industrial Park of Suzhou city in Jiangsu province 215123 No. 399 southeast Hospital No. 1 503 Applicant before: CHEMOGENE BIOTECHNOLOGIES SUZHOU Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160510 Address after: 230088 Customs Road, 669 hi tech Zone, Changjiang West Road, Anhui, Hefei K1 Patentee after: ANHUI ANKE BIOTECHNOLOGY (Group) Co.,Ltd. Address before: 650200, No. 2, unit 5, 31 Tung Wan, Guandu District, Yunnan, Kunming Patentee before: Zhang Yingpin |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140917 |
|
CF01 | Termination of patent right due to non-payment of annual fee |